Literature DB >> 11493374

Isoprostane 8-epi-PGF2alpha is frequently increased in patients with muscle pain and/or CK-elevation after HMG-Co-enzyme-A-reductase inhibitor therapy.

H Sinzinger1, G Lupattelli, F Chehne, A Oguogho, C D Furberg.   

Abstract

BACKGROUND: Muscle pains with or without CK-elevation are among the most frequently observed side-effects in patients with hyperlipoproteinemia on various statins. The pathophysiological background, however, remains obscure.
METHODS: We examined isoprostane 8-epi-PGF2alpha, a marker of in-vivo oxidation injury, in plasma, serum and urine in these patients at baseline, when muscle problems manifested and different time intervals after withdrawing the respective statin. A healthy control group and a group of untreated patients with hyperlipoproteinemia were run as controls.
RESULTS: The majority of patients with muscular side-effects show elevated 8-epi-PGF2alpha in plasma and urine, whereas serum values were elevated only to a lesser extent. Stopping statin therapy or successfully changing to another member of this family of compounds resulted in a normalization of the values in all patients.
CONCLUSION: These findings indicate a significant involvement of oxidative injury in the muscular side-effects of statins in patients suffering from hyperlipoproteinemia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11493374     DOI: 10.1046/j.1365-2710.2001.00360.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  10 in total

1.  Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems.

Authors:  H Sinzinger; J O'Grady
Journal:  Br J Clin Pharmacol       Date:  2004-04       Impact factor: 4.335

2.  Statin-associated muscle-related adverse effects: a case series of 354 patients.

Authors:  Stephanie Cham; Marcella A Evans; Julie O Denenberg; Beatrice A Golomb
Journal:  Pharmacotherapy       Date:  2010-06       Impact factor: 4.705

3.  Amyotrophic Lateral Sclerosis Associated with Statin Use: A Disproportionality Analysis of the FDA's Adverse Event Reporting System.

Authors:  Beatrice A Golomb; Abril Verden; Alexis K Messner; Hayley J Koslik; Keith B Hoffman
Journal:  Drug Saf       Date:  2018-04       Impact factor: 5.606

4.  Impact of atorvastatin treatment on platelet-activating factor acetylhydrolase and 15-F(2trans)-isoprostane in hypercholesterolaemic patients.

Authors:  Ghainsom D Kom; Edzard Schwedhelm; Renke Maas; Lydia Schneider; Ralf Benndorf; Rainer H Böger
Journal:  Br J Clin Pharmacol       Date:  2007-01-03       Impact factor: 4.335

5.  Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study.

Authors:  Beatrice A Golomb; Edwin K Kwon; Sabrina Koperski; Marcella A Evans
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

6.  Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance.

Authors:  Beatrice A Golomb; John J McGraw; Marcella A Evans; Joel E Dimsdale
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 7.  Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism.

Authors:  Beatrice A Golomb; Marcella A Evans
Journal:  Am J Cardiovasc Drugs       Date:  2008       Impact factor: 3.571

8.  Oxidation-sensitive nociception involved in endometriosis-associated pain.

Authors:  Kristeena Ray; Johannes Fahrmann; Brenda Mitchell; Dennis Paul; Holly King; Courtney Crain; Carla Cook; Mikhail Golovko; Stephen Brose; Svetlana Golovko; Nalini Santanam
Journal:  Pain       Date:  2015-03       Impact factor: 7.926

9.  Statin Effects on Aggression: Results from the UCSD Statin Study, a Randomized Control Trial.

Authors:  Beatrice A Golomb; Joel E Dimsdale; Hayley J Koslik; Marcella A Evans; Xun Lu; Steven Rossi; Paul J Mills; Halbert L White; Michael H Criqui
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

10.  Mood, Personality, and Behavior Changes During Treatment with Statins: A Case Series.

Authors:  Stephanie Cham; Hayley J Koslik; Beatrice A Golomb
Journal:  Drug Saf Case Rep       Date:  2016-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.